Retinitis Pigmentosa and Therapeutic Approaches: A Systematic Review

Author:

Confalonieri Filippo12ORCID,La Rosa Antonio1,Ottonelli Giovanni1,Barone Gianmaria1ORCID,Ferraro Vanessa1,Di Maria Alessandra2ORCID,Romano Mary2,Randazzo Alessandro2,Vallejo-Garcia Josè Luis2,Vinciguerra Paolo12,Petrovski Goran3456ORCID

Affiliation:

1. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy

2. Department of Ophthalmology, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy

3. Center for Eye Research and Innovative Diagnostics, Department of Ophthalmology, Institute for Clinical Medicine, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway

4. Department of Ophthalmology, Oslo University Hospital, Kirkeveien 166, 0450 Oslo, Norway

5. Department of Ophthalmology, University of Split School of Medicine and University Hospital Centre, 21000 Split, Croatia

6. UKLONetwork, University St. Kliment Ohridski-Bitola, 7000 Bitola, North Macedonia

Abstract

Background: Retinitis pigmentosa (RP) is a group of hereditary retinal dystrophies characterized by progressive degeneration of photoreceptor cells, which results in debilitating visual impairment. This systematic review aims to evaluate the efficacy and safety of emerging treatment modalities for RP, including gene therapy, mesenchymal-cell-based approaches, and supplementary interventions. Methods: A comprehensive search of electronic databases was conducted to identify relevant studies published up to February 2024. Studies reporting outcomes of treatment interventions for RP, including randomized controlled trials, non-randomized studies, and case series, were included. Data extraction and synthesis were performed according to predefined criteria, focusing on assessing the quality of evidence and summarizing key findings. Results: The search yielded 13 studies meeting inclusion criteria, encompassing diverse treatment modalities and study designs. Gene therapy emerged as a promising therapeutic approach, with several studies reporting favorable outcomes regarding visual function preservation and disease stabilization. Mesenchymal-cell-based therapies also demonstrated potential benefits, although evidence remains limited and heterogeneous. Supplementary interventions, including nutritional supplements and neuroprotective agents, exhibited variable efficacy, with conflicting findings across studies. Conclusions: Despite the lack of definitive curative treatments, emerging therapeutic modalities promise to slow disease progression and preserve visual function in individuals with RP. However, substantial gaps in evidence and heterogeneity in study methodologies underscore the need for further research to elucidate optimal treatment strategies, refine patient selection criteria, and enhance long-term outcomes. This systematic review provides a comprehensive synthesis of current evidence and highlights directions for future research to advance the care and management of individuals with RP.

Publisher

MDPI AG

Reference58 articles.

1. Retinitis pigmentosa;Hamel;Orphanet J. Rare Dis.,2006

2. Retinitis Pigmentosa: Burden of Disease and Current Unmet Needs;Cross;Clin. Ophthalmol.,2022

3. Monitoring progression of retinitis pigmentosa: Current recommendations and recent advances;Menghini;Expert Opin. Orphan Drugs,2020

4. Emerging Treatments for Retinitis Pigmentosa: Genes and stem cells, as well as new electronic and medical therapies, are gaining ground;Lin;Retin. Physician,2015

5. Rayyan—A web and mobile app for systematic reviews;Ouzzani;Syst. Rev.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3